AI Science Tracker

Collaborations Pharmaceuticals

2 discoveries from 2021 to 2022

Discoveries

Prospective machine-learning screen identifies six previously unreported OATP1B1 inhibitors

Researchers trained and compared seven machine-learning classifiers for OATP1B1 transporter inhibition. In prospective CHO-cell testing, 15 of 19 compounds predicted active by SVC models inhibited the transporter; six (abamectin, asiaticoside, berbamine, doramectin, mobocertinib and umbralisib) were described as previously unreported OATP1B1 inhibitors.

Technology: Seven molecular-fingerprint machine-learning classifiers, with prospective selection by support vector classifier (SVC)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: In prospective CHO-cell testing, 15 of 19 compounds predicted active by SVC models inhibited the transporter; six (abamectin, asiaticoside, berbamine, doramectin, mobocertinib and umbralisib) were described as previously unreported OATP1B1 inhibitors. The new candidate screen used contracted Eurofins assays; external execution is not a separate replication study.
  • Still unknown: The 84% refers to a small prospective test set of 19 compounds, and transporter inhibition was measured in vitro in engineered CHO cells. These findings flag possible drug–drug interaction liability; they do not show clinical interaction or patient outcome. The authors qualify six inhibitors as appearing novel at publication.
  • AI role: Models trained on in-vitro OATP1B1 inhibition data ranked compounds for prospective testing. Researchers tested 19 model-selected compounds in transporter-expressing CHO cells and observed inhibition for 15, including six compounds the authors described as novel OATP1B1 inhibitors.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9873312/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 89 of works of the same type, year and subfield (OpenAlex work metrics, 31 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Bayesian models prioritize compounds for Schistosoma mansoni assays

Eight stage/time-specific Bayesian classifiers trained on historical phenotypic measurements guided prospective selection of predicted active and inactive commercial compounds. In-vitro assays reported 48% and 34% hit fractions for somules and adults, followed by triage of five compounds. The selected-set fractions are not unbiased head-to-head screening rates; no animal cure, clinical mechanism, safety or efficacy is established.

Technology: Bayesian classifiers

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Primary article reports prospective somule/adult screens and prioritized compounds after triage.
  • Still unknown: Compound-specific prior evidence and complete supplementary access remain open; no clinical inference.
  • AI role: Stage/time-specific Bayesian models guided selection of assay compounds, with human curation and triage.

Evidence sources: https://doi.org/10.1021/acsinfecdis.0c00754

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 16 Nov 2026. Review scope: PMC-indexed primary text; PubMed primary metadata. Material checked for the specific claims stated in the record..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.